WO1996017072A3 - Recombinant alphavirus vectors - Google Patents
Recombinant alphavirus vectors Download PDFInfo
- Publication number
- WO1996017072A3 WO1996017072A3 PCT/US1995/015490 US9515490W WO9617072A3 WO 1996017072 A3 WO1996017072 A3 WO 1996017072A3 US 9515490 W US9515490 W US 9515490W WO 9617072 A3 WO9617072 A3 WO 9617072A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alphavirus vectors
- recombinant alphavirus
- vectors
- recombinant
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU45949/96A AU4594996A (en) | 1994-11-30 | 1995-11-30 | Recombinant alphavirus vectors |
EP95944045A EP0797679A2 (en) | 1994-11-30 | 1995-11-30 | Recombinant alphavirus vectors |
JP8519023A JPH11504802A (en) | 1994-11-30 | 1995-11-30 | Recombinant alphavirus vector |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34847294A | 1994-11-30 | 1994-11-30 | |
US08/348,472 | 1994-11-30 | ||
US37618495A | 1995-01-18 | 1995-01-18 | |
US08/376,184 | 1995-01-18 | ||
US40582795A | 1995-03-15 | 1995-03-15 | |
US08/405,827 | 1995-03-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1996017072A2 WO1996017072A2 (en) | 1996-06-06 |
WO1996017072A9 WO1996017072A9 (en) | 1996-10-24 |
WO1996017072A3 true WO1996017072A3 (en) | 1997-04-17 |
Family
ID=27407843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/015490 WO1996017072A2 (en) | 1994-11-30 | 1995-11-30 | Recombinant alphavirus vectors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4594996A (en) |
WO (1) | WO1996017072A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9913892B2 (en) | 2005-04-21 | 2018-03-13 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US11850305B2 (en) | 2010-07-06 | 2023-12-26 | Glaxosmithkline Biologicals Sa | Method of making lipid formulations with RNA encoding immunogens |
US11851660B2 (en) | 2010-07-06 | 2023-12-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
Families Citing this family (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
JP2001517063A (en) * | 1995-06-07 | 2001-10-02 | アボツト・ラボラトリーズ | Adenosine kinase polynucleotide |
DE19604858A1 (en) * | 1996-02-10 | 1997-08-14 | Boehringer Ingelheim Int | Interferon-gamma for treating or preventing amyloid precursor protein related diseases |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US6465634B1 (en) | 1996-04-05 | 2002-10-15 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
PT918874E (en) * | 1996-08-16 | 2001-08-30 | Medical Res Council | EPISOMIC AUTHORSPRODUCTION EXPRESSION VECTORS CONFERING A GENERA SPECIFIC EXPRESSION OF THE FABRICS |
CA2268353A1 (en) * | 1996-10-10 | 1998-04-16 | Henrik Garoff | Alphavirus-retrovirus vectors |
US5811407A (en) * | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US6432699B1 (en) * | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
CA2291010A1 (en) | 1997-06-02 | 1998-12-10 | Chiron Corporation | Herpes simplex virus vp22 vaccines and methods of use |
WO1999009192A1 (en) * | 1997-08-15 | 1999-02-25 | Inex Pharmaceuticals Corporation | Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells |
WO1999012038A1 (en) * | 1997-09-01 | 1999-03-11 | Muller Claude P | Detection of measles virus-specific antibodies |
US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
BR9814171A (en) * | 1997-11-14 | 2001-10-30 | Connaught Lab | Modified alphavirus expression vector |
EP1707633A1 (en) * | 1997-11-14 | 2006-10-04 | Sanofi Pasteur Limited | Alphavirus vectors for paramyxovirus vaccines |
AU749345B2 (en) | 1997-11-14 | 2002-06-27 | Connaught Laboratories Limited | Alphavirus vectors for paramyxovirus vaccines |
IL138615A0 (en) | 1998-03-27 | 2001-10-31 | Cytos Biotechnology Ag | Alphaviral gene expression system and dna molecules for use therein |
US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
EP1100545A4 (en) * | 1998-07-29 | 2002-03-20 | Invitrogen Corp | Regulated expression of recombinant proteins using rna viruses |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
WO2000039302A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
WO2001042442A2 (en) | 1999-12-10 | 2001-06-14 | Cytos Biotechnology Ag | Activation of endogenous genes by genomic introduction of a replicon |
US20030143528A1 (en) * | 2000-05-15 | 2003-07-31 | Michinori Kohara | Vector for analayzing replication mechanism of rna virus and use thereof |
CA2410948C (en) | 2000-05-31 | 2012-07-17 | Chiron Corporation | Method for the purification of alphavirus replicon particles |
US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
EP1370684B1 (en) | 2000-06-15 | 2008-05-28 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides related to colon cancer |
US6982087B2 (en) | 2000-09-07 | 2006-01-03 | The University Of North Carolina At Chapel Hill | Vectors derived from South African Arbovirus No. 86 |
WO2002046477A2 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
EP2412242A3 (en) | 2001-07-05 | 2012-06-13 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
WO2003004657A1 (en) | 2001-07-05 | 2003-01-16 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
DE60233061D1 (en) | 2001-09-06 | 2009-09-03 | Alphavax Inc | ALPHAVIRUS REPLICON VECTOR SYSTEMS |
AU2002359446B2 (en) | 2001-11-09 | 2008-12-04 | Georgetown University | Novel isoforms of vascular endothelial cell growth inhibitor |
US7195905B2 (en) * | 2001-12-10 | 2007-03-27 | Baxter Healthcare S.A. | Enveloped virus vaccine and method for production |
DE60326931D1 (en) | 2002-01-08 | 2009-05-14 | Novartis Vaccines & Diagnostic | DIFFERENTIALLY EXPRESSED GENEVA PRODUCTS AND THEIR USE PROCEDURES IN CANNULAR MAMMA CELLS |
AU2003218350A1 (en) | 2002-03-21 | 2003-10-08 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
EP1532161B1 (en) | 2002-06-13 | 2012-02-15 | Novartis Vaccines and Diagnostics, Inc. | Vectors for expression of hml-2 polypeptides |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
ES2618309T3 (en) | 2002-12-13 | 2017-06-21 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
NZ540657A (en) | 2002-12-13 | 2006-09-29 | Alphavax Inc | High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
CA2516138A1 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
ATE491444T1 (en) | 2003-02-19 | 2011-01-15 | Rinat Neuroscience Corp | METHOD FOR TREATING PAIN BY ADMINISTRATION OF A NERVE GROWTH FACTOR ANTAGONIST AND AN NSAID AND COMPOSITION CONTAINING THE SAME |
KR101454842B1 (en) | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | Improved alphavirus replicons and helper constructs |
EP1628680B1 (en) | 2003-05-15 | 2012-10-24 | Novartis Vaccines and Diagnostics, Inc. | Hiv polynucleotides and polypeptides derived from botswana mj4 |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
EP1644508A1 (en) | 2003-07-11 | 2006-04-12 | Cytos Biotechnology AG | Gene expression system |
AU2004257214B2 (en) | 2003-07-11 | 2010-04-22 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
SG166768A1 (en) | 2003-12-23 | 2010-12-29 | Rinat Neuroscience Corp | Agonist anti-trkc antibodies and methods using same |
KR101504729B1 (en) | 2004-04-07 | 2015-03-19 | 리나트 뉴로사이언스 코프. | Pharmaceutical composotion for treating bone cancer pain by administering a nerve growth factor antagonist |
US7622125B2 (en) | 2004-05-05 | 2009-11-24 | Novartis Vaccines And Diagnostics, Inc. | Polycistronic HIV vector constructs |
US20050266550A1 (en) | 2004-05-18 | 2005-12-01 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
CA2572921C (en) | 2004-07-09 | 2017-01-03 | The University Of North Carolina At Chapel Hill | Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants |
PT1789593T (en) | 2004-07-09 | 2017-04-24 | Henry M Jackson Found Advancement Military Medicine Inc | Soluble forms of hendra virus g glycoprotein |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
MX2007000998A (en) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same. |
US20100015211A1 (en) | 2004-11-01 | 2010-01-21 | Barnett Susan W | Combination Approaches For Generating Immune Responses |
CA2597921A1 (en) | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
CN101203529A (en) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
AU2006235276A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | CACNA1E in cancer diagnosis, detection and treatment |
WO2006110585A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes (prlr) |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
KR20080039929A (en) | 2005-07-22 | 2008-05-07 | 와이스 테라퓨틱스 가부시키가이샤 | Anti-cd26 antibodies and methods of use thereof |
ES2433251T5 (en) | 2005-11-14 | 2020-03-13 | Teva Pharmaceuticals Int Gmbh | Antagonistic antibodies directed against a peptide related to the calcitonin gene and procedures using them |
JP5215865B2 (en) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | Norovirus and sapovirus antigens |
WO2007088479A1 (en) | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
KR101496433B1 (en) | 2006-06-07 | 2015-02-26 | 바이오얼라이언스 씨.브이. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
PT2520168E (en) | 2006-07-21 | 2014-04-29 | California Inst Of Techn | Targeted gene delivery for dendritic cell vaccination |
EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
WO2008124176A2 (en) | 2007-04-10 | 2008-10-16 | The Administrators Of The Tulane Educational Fund | Soluble and membrane-anchored forms of lassa virus subunit proteins |
WO2008156829A2 (en) | 2007-06-21 | 2008-12-24 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
US20120040367A1 (en) | 2007-10-15 | 2012-02-16 | The University Of Queensland | Construct system and uses therefor |
WO2009077993A2 (en) | 2007-12-17 | 2009-06-25 | Pfizer Limited | Treatment of interstitial cystitis |
AU2008338313B2 (en) | 2007-12-18 | 2014-01-16 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
WO2009126306A2 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
US8568732B2 (en) | 2009-03-06 | 2013-10-29 | Novartis Ag | Chlamydia antigens |
WO2010118243A2 (en) | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Use of il-27 antagonists to treat lupus |
EP3263128A3 (en) | 2009-04-14 | 2018-01-24 | GlaxoSmithKline Biologicals S.A. | Compositions for immunising against staphylococcus aureus |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
MX2012000734A (en) | 2009-07-16 | 2012-01-27 | Novartis Ag | Detoxified escherichia coli immunogens. |
PL2456786T5 (en) | 2009-07-24 | 2017-10-31 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
TWI552760B (en) | 2010-02-24 | 2016-10-11 | 雷那特神經科學股份有限公司 | Antagonist anti-il-7 receptor antibodies and methods |
US20130052221A1 (en) | 2010-02-26 | 2013-02-28 | The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services | Dna-protein vaccination protocols |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
CN102844332B (en) | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | The antibody combined in pH dependence antigen |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
ES2770335T3 (en) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | RNA administration to trigger multiple immune pathways |
WO2012015758A2 (en) | 2010-07-30 | 2012-02-02 | Saint Louis University | Methods of treating pain |
LT3981427T (en) | 2010-08-31 | 2022-08-10 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
MX363307B (en) | 2010-10-11 | 2019-03-20 | Novartis Ag Star | Antigen delivery platforms. |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
US20130071375A1 (en) | 2011-08-22 | 2013-03-21 | Saint Louis University | Compositions and methods for treating inflammation |
WO2013028527A1 (en) | 2011-08-23 | 2013-02-28 | Indiana University Research And Technology Corporation | Compositions and methods for treating cancer |
AU2012335205A1 (en) | 2011-11-11 | 2014-05-29 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
WO2013082106A1 (en) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
AU2012356206A1 (en) | 2011-12-22 | 2014-06-26 | Rinat Neuroscience Corp. | Human growth hormone receptor antagonist antibodies and methods of use thereof |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
EA038702B1 (en) | 2012-03-30 | 2021-10-07 | Иммьюн Дизайн Корп. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc sign |
JP6246199B2 (en) | 2012-07-02 | 2017-12-13 | ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | Paramyxovirus and usage |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
EP2890720B1 (en) | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Compositions and methods for treating cancer |
RU2015115956A (en) | 2012-11-09 | 2017-01-10 | Пфайзер Инк. | ANTIBODIES SPECIFIC TO THE THROMBOCYTE B GROWTH FACTOR, AND THEIR COMPOSITION AND APPLICATION |
SG11201507462QA (en) * | 2013-03-14 | 2015-10-29 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
WO2014152232A2 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
CA3182572A1 (en) | 2013-04-17 | 2014-10-23 | Genzyme Corporation | Use of an il17 inhibitor for treating and preventing macular degeneration |
KR20160005749A (en) | 2013-05-07 | 2016-01-15 | 리나트 뉴로사이언스 코프. | Anti-glucagon receptor antibodies and methods of use thereof |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
CN106211774B (en) | 2013-08-02 | 2020-11-06 | 辉瑞公司 | anti-CXCR 4 antibodies and antibody-drug conjugates |
CA3056647A1 (en) | 2013-11-13 | 2015-05-21 | Robert ARCH | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
EP3068783B1 (en) | 2013-11-15 | 2020-09-23 | The Board of Trustees of the Leland Stanford Junior University | Agonists of hypocretin receptor 2 for use for treating heart failure |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
EP3102246B1 (en) | 2014-02-06 | 2020-03-25 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
UA123759C2 (en) | 2014-03-21 | 2021-06-02 | Тева Фармасьютікалз Інтернешнл Гмбх | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US10308697B2 (en) | 2014-04-30 | 2019-06-04 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
JP7095990B2 (en) | 2014-09-18 | 2022-07-05 | シーダーズ-サイナイ メディカル センター | Compositions and Methods for Treating Fibrosis |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
KR102405104B1 (en) | 2015-04-13 | 2022-06-07 | 화이자 인코포레이티드 | Therapeutic antibodies and their uses |
US20180112006A1 (en) | 2015-04-17 | 2018-04-26 | The General Hospital Corporation | Agents, systems and methods for treating cancer |
US20180110823A1 (en) | 2015-04-22 | 2018-04-26 | Cedars-Sinai Medical Center | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes |
WO2016183420A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for inducing an immune response using conserved element constructs |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
US10550379B2 (en) | 2015-06-29 | 2020-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
US10877045B2 (en) | 2015-07-21 | 2020-12-29 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
EA201890340A1 (en) | 2015-07-21 | 2018-09-28 | Дайэкс Корп. | MONOCLONAL ANTIBODY-INHIBITOR OF FACTOR XIIA |
CA3025896A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
SG10201912817YA (en) | 2015-08-19 | 2020-02-27 | Pfizer | Tissue factor pathway inhibitor antibodies and uses thereof |
EA038146B1 (en) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3365369A1 (en) | 2015-10-23 | 2018-08-29 | Pfizer Inc | Anti-il-2 antibodies and compositions and uses thereof |
CN106699889A (en) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技(上海)有限公司 | PD-1 resisting antibody and treatment application thereof |
WO2017096432A1 (en) | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
KR20180104635A (en) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | Antibodies and conjugates thereof |
US10221242B2 (en) | 2016-01-21 | 2019-03-05 | Pfizer Inc. | Antibodies specific for epidermal growth factor receptor variant III and their uses |
CN110431152A (en) | 2017-03-03 | 2019-11-08 | 雷纳神经科学公司 | Anti- GITR antibody and its application method |
CA3056182A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
AU2018250695A1 (en) | 2017-04-14 | 2019-11-07 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
EP3630841A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
EP3879535A1 (en) | 2017-06-13 | 2021-09-15 | BostonGene Corporation | Systems and methods for identifying cancer treatments from normalized biomarker scores |
WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | Anti-nucleolin antibody |
KR20210027230A (en) | 2017-10-04 | 2021-03-10 | 옵코 파마슈티칼스, 엘엘씨 | Articles and methods for personalized treatment of cancer |
TW201936633A (en) | 2018-02-01 | 2019-09-16 | 美商輝瑞大藥廠 | Chimeric antigen receptors targeting CD70 |
BR112020015641A2 (en) | 2018-02-01 | 2021-01-05 | Pfizer Inc. | SPECIFIC ANTIBODIES FOR CD70 AND ITS USES |
PE20201342A1 (en) | 2018-02-28 | 2020-11-25 | Pfizer | VARIANTS OF IL-15 AND USES OF THE SAME |
BR112020022595A2 (en) | 2018-05-23 | 2021-02-09 | Pfizer Inc. | specific antibodies to gucy2c and uses thereof |
BR112020022897A2 (en) | 2018-05-23 | 2021-02-23 | Pfizer Inc. | specific antibodies to cd3 and their uses |
US20210005283A1 (en) | 2019-07-03 | 2021-01-07 | Bostongene Corporation | Techniques for bias correction in sequence data |
EP4041308A1 (en) | 2019-10-07 | 2022-08-17 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
CN114786731A (en) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | Methods of treating ocular disorders |
CA3152623A1 (en) | 2019-10-11 | 2021-04-15 | Richard D. Cummings | Anti-tn antibodies and uses thereof |
WO2021151079A1 (en) | 2020-01-24 | 2021-07-29 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
WO2021205325A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
US20230181750A1 (en) | 2020-05-06 | 2023-06-15 | Crispr Therapeutics Ag | Mask peptides and masked anti-ptk7 antibodies comprising such |
CA3189590A1 (en) | 2020-07-17 | 2022-01-20 | Pfizer Inc. | Therapeutic antibodies and their uses |
CA3190227A1 (en) | 2020-07-30 | 2022-02-03 | Pfizer Inc. | Cells having gene duplications and uses thereof |
WO2022120256A2 (en) | 2020-12-04 | 2022-06-09 | Bostongene Corporation | Hierarchical machine learning techniques for identifying molecular categories from expression data |
US20220372580A1 (en) | 2021-04-29 | 2022-11-24 | Bostongene Corporation | Machine learning techniques for estimating tumor cell expression in complex tumor tissue |
CA3227875A1 (en) | 2021-08-02 | 2023-02-09 | Pfizer Inc. | Improved expression vectors and uses thereof |
WO2023070072A1 (en) | 2021-10-21 | 2023-04-27 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Retroelement-generated transcription factor decoys |
WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
US20230245479A1 (en) | 2022-01-31 | 2023-08-03 | Bostongene Corporation | Machine learning techniques for cytometry |
WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
WO2023183627A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna |
WO2023183588A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods of assessing engineered retron activity, and uses thereof |
WO2023183589A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Rt-dna fidelity and retron genome editing |
WO2024015561A1 (en) | 2022-07-15 | 2024-01-18 | Bostongene Corporation | Techniques for detecting homologous recombination deficiency (hrd) |
WO2024020346A2 (en) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Gene editing components, systems, and methods of use |
WO2024044673A1 (en) | 2022-08-24 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Dual cut retron editors for genomic insertions and deletions |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017813A1 (en) * | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
WO1995007994A2 (en) * | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
-
1995
- 1995-11-30 AU AU45949/96A patent/AU4594996A/en not_active Abandoned
- 1995-11-30 WO PCT/US1995/015490 patent/WO1996017072A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017813A1 (en) * | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
WO1995007994A2 (en) * | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
Non-Patent Citations (5)
Title |
---|
A. GRAKOUI ET AL.: "A cis-acting mutation in the Sindbis virus junction region which affects subgenomic RNA synthesis", J. VIROL., vol. 63, 1989, pages 5216 - 5227, XP002007911 * |
J. CELL. BIOCHEM., Suppl., 19A (1995), p. 228, abstract no. A6-413, J.M. POLO ET AL. "Alphavirus mediated delivery of ribozyme therapeutics" * |
Keystone Symposium on Ribozymes: Basic Science and Terapeutic Applications, Breckenridge, Colorado, USA, Jan. 15-21, 1995. * |
R. RAJU ET AL.: "Analysis of Sindbis virus promoter recognition in vivo, using novel vectors with two subgenomic mRNA promoters", J. VIROL., vol. 65, 1991, pages 2501 - 2510, XP002007912 * |
S. SCHLESINGER: "Alphaviruses - vectors for the expression of heterologous genes", TRENDS IN BIOTECHNOL., vol. 11, 1993, pages 18 - 22, XP002007913 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9913892B2 (en) | 2005-04-21 | 2018-03-13 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US11850305B2 (en) | 2010-07-06 | 2023-12-26 | Glaxosmithkline Biologicals Sa | Method of making lipid formulations with RNA encoding immunogens |
US11851660B2 (en) | 2010-07-06 | 2023-12-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
Also Published As
Publication number | Publication date |
---|---|
WO1996017072A2 (en) | 1996-06-06 |
AU4594996A (en) | 1996-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996017072A3 (en) | Recombinant alphavirus vectors | |
WO1995007994A3 (en) | Recombinant alphavirus vectors | |
EP0650844A3 (en) | Shuttle-type-printers and methods for operating same. | |
EP1400523A3 (en) | Intermediate compounds | |
PH31158A (en) | Cosmetic composition. | |
YU15299A (en) | Pharmaceutical compositions | |
ZA9711239B (en) | OB fusion protein compositions and methods. | |
ZA967964B (en) | Compositions and methods for controlling harmful fungi. | |
AU4565197A (en) | Colostrinin, and uses thereof | |
EP0684283A3 (en) | Resin composition for sliding member and sliding member. | |
CA2301717A1 (en) | Peptide with radio protective effect | |
ZA975261B (en) | Composition. | |
EP0761683A4 (en) | Protein or polypeptide, process for producing the same, and intermediate compound tehrefor | |
WO1997030082A3 (en) | Antifungic and antibacterial peptide | |
EP0614944A3 (en) | Intumescent composition of the two-components-type. | |
ZA967463B (en) | Compositions and methods for controlling harmful fungi. | |
GB9608488D0 (en) | Compositions, processes and uses | |
GB9608485D0 (en) | Compositions, processes and uses | |
HK1001404A1 (en) | Isolated, tyrosinase derived peptides and uses thereof. | |
GR3031122T3 (en) | Stable lyophilized thiotepa composition. | |
EP0679658A4 (en) | Endothelin-antagonizing peptide. | |
AU2316897A (en) | Cyclic imido-1,3,5-triazine crosslinking agents | |
EP0649879A3 (en) | High tear strength silicone compositions. | |
EP0664113A3 (en) | Hairdressing composition. | |
AU4088097A (en) | Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/27-22/27 AND 24/27-27/27,DRAWINGS,REPLACED BY NEW PAGES 1/26-21/26 AND 23/26-26/26,AND PAGE23/27 RENUMBERED AS PAGE 22/26;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1996 519023 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995944045 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995944045 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995944045 Country of ref document: EP |